Federal Register of Legislation - Australian Government

Primary content

Determinations/Health as made
This instrument amends the Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018 to allow access to BRAF V600 gene variant testing for patients with metastatic colorectal cancer.
Administered by: Health and Aged Care
General Comments: This instrument was registered at 7.26 pm (by legal time in the Australian Capital Territory) on 17 January 2022.
Registered 17 Jan 2022
Tabling HistoryDate
Tabled HR08-Feb-2022
Tabled Senate08-Feb-2022
Date of repeal 08 Sep 2022
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.

Commonwealth Coat of Arms of Australia

 

Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 1) 2022

I, Louise Riley, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated      17 January 2022

           

Louise Riley

Acting First Assistant Secretary

Medical Benefits Division

Health Resourcing Group

Department of Health

 

 

 


Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1— Amendments                                                                                          2

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018                          2

 

 


1  Name

                        This instrument is the Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 1) 2022.

2  Commencement

(1)       Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1. Sections 1 to 4

Immediately after registration of this instrument

 

2. Schedule 1

This Schedule is taken to have commenced on 1 January 2022

 

                Note:        This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)       Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                        This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.

4  Schedules

                        Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


 

Schedule 1— Amendments

 

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018

1.    Schedule 1 (cell at item 73338, column 2)

Repeal the cell, substitute:

            A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if:

(a)      requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if:

(i)       the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or

(ii)     a clinically-relevant RAS variant is detected;

and, in cases where no RAS variant is detected:

(b)      the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.